FI3509582T3 - (r)-2-amino-3-fenyylipropyylikarbamaatin solvaattimuoto - Google Patents
(r)-2-amino-3-fenyylipropyylikarbamaatin solvaattimuoto Download PDFInfo
- Publication number
- FI3509582T3 FI3509582T3 FIEP17849432.4T FI17849432T FI3509582T3 FI 3509582 T3 FI3509582 T3 FI 3509582T3 FI 17849432 T FI17849432 T FI 17849432T FI 3509582 T3 FI3509582 T3 FI 3509582T3
- Authority
- FI
- Finland
- Prior art keywords
- composition
- amino
- chloropropane
- phenylpropylcarbamate
- hydrochloride
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C271/20—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by nitrogen atoms not being part of nitro or nitroso groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C271/12—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C269/00—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C269/08—Separation; Purification; Stabilisation; Use of additives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Child & Adolescent Psychology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Addiction (AREA)
- Emergency Medicine (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662383822P | 2016-09-06 | 2016-09-06 | |
| PCT/US2017/050233 WO2018048871A1 (en) | 2016-09-06 | 2017-09-06 | Solvate form of (r)-2-amino-3-phenylpropyl carbamate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FI3509582T3 true FI3509582T3 (fi) | 2024-02-08 |
Family
ID=61562003
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FIEP17849432.4T FI3509582T3 (fi) | 2016-09-06 | 2017-09-06 | (r)-2-amino-3-fenyylipropyylikarbamaatin solvaattimuoto |
Country Status (13)
| Country | Link |
|---|---|
| US (4) | US10829443B2 (https=) |
| EP (2) | EP4364794A3 (https=) |
| JP (3) | JP7219213B2 (https=) |
| KR (1) | KR102513800B1 (https=) |
| CN (4) | CN109996540A (https=) |
| CA (1) | CA3036071A1 (https=) |
| DK (1) | DK3509582T3 (https=) |
| ES (1) | ES2970887T3 (https=) |
| FI (1) | FI3509582T3 (https=) |
| MY (1) | MY197630A (https=) |
| PH (1) | PH12019500493A1 (https=) |
| SG (1) | SG11201901998WA (https=) |
| WO (1) | WO2018048871A1 (https=) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11602512B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US12186296B1 (en) | 2016-07-22 | 2025-01-07 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11504347B1 (en) | 2016-07-22 | 2022-11-22 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US12478604B1 (en) | 2016-07-22 | 2025-11-25 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| UY37341A (es) | 2016-07-22 | 2017-11-30 | Flamel Ireland Ltd | Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada |
| US11602513B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11986451B1 (en) | 2016-07-22 | 2024-05-21 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| ES2970887T3 (es) | 2016-09-06 | 2024-05-31 | Axsome Malta Ltd | Forma de solvato de carbamato de (R)-2-amino-3-fenilpropilo |
| EP3837239A4 (en) | 2018-08-14 | 2022-05-18 | Glenmark Life Sciences Limited | PROCESS FOR THE PREPARATION OF SOLRIAMFETOL AND SALT THEREOF |
| EP3930702A1 (en) | 2019-03-01 | 2022-01-05 | Flamel Ireland Limited | Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state |
| WO2021001457A1 (en) | 2019-07-04 | 2021-01-07 | Sandoz Ag | Crystalline (r)-2-amino-3-phenylpropylcarbamate acid addition salts |
| IT202000013855A1 (it) | 2020-06-10 | 2021-12-10 | Flamma Spa | Un processo per la purificazione del (r)-2-ammino-3-fenilpropil carbammato |
| US11583510B1 (en) | 2022-02-07 | 2023-02-21 | Flamel Ireland Limited | Methods of administering gamma hydroxybutyrate formulations after a high-fat meal |
| US11779557B1 (en) | 2022-02-07 | 2023-10-10 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| AU2023375326A1 (en) * | 2022-11-07 | 2025-05-22 | Axsome Therapeutics | Compositions and methods for treating insomnia |
| CN120641090A (zh) * | 2022-12-30 | 2025-09-12 | 阿克苏姆马耳他有限公司 | 向哺乳期女性施用索安非托的方法 |
| WO2024194718A1 (en) | 2023-03-22 | 2024-09-26 | Unichem Laboratories Limited | A stable pharmaceutical composition and process for preparing thereof |
| EP4719375A1 (en) | 2023-05-30 | 2026-04-08 | Axsome Therapeutics, Inc. | Solriamfetol for treating cognitive impairment in a subject with impaired cognition associated with obstructive sleep apnea and excessive daytime sleepiness |
| KR20260033050A (ko) | 2023-06-29 | 2026-03-10 | 액섬 테라퓨틱스, 인크. | 수유 여성에게 솔리암페톨을 투여하는 방법 |
| WO2025042959A1 (en) | 2023-08-21 | 2025-02-27 | Axsome Therapeutics, Inc. | Use of solriamfetol for the treatment of orphan diseases |
| WO2025165760A1 (en) * | 2024-01-29 | 2025-08-07 | Axsome Therapeutics, Inc. | Phenylalkylamino carbamates for use in the treatment of attention deficit/hyperactivity disorder |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100197892B1 (ko) | 1994-09-09 | 1999-06-15 | 남창우 | 신규한 페닐알킬아미노 카바메이트 화합물과 그의 제조방법 |
| US5756817C1 (en) | 1995-02-11 | 2001-04-17 | Sk Corp | O-carbamoyl-phenylananinol compounds their pharmaceutically useful salts and process for preparing the same |
| KR0173862B1 (ko) | 1995-02-11 | 1999-04-01 | 조규향 | O-카바모일-(d)-페닐알라닌올 화합물과 그의 약제학적으로 유용한 염 및 이들의 제조방법 |
| KR0173863B1 (ko) | 1995-04-10 | 1999-04-01 | 조규향 | 페닐에 치환체가 있는 o-카바모일-페닐알라닌올 화합물과 그의 약제학적으로 유용한 염 및 이들의 제조방법 |
| CA2355293C (en) | 1998-12-23 | 2005-08-16 | Orphan Medical, Inc. | Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy |
| RU2202607C2 (ru) | 2000-03-03 | 2003-04-20 | Закрытое акционерное общество "Научно-исследовательский институт Аджиномото-Генетика" | Штамм бактерий methylophilus methylotrophus - продуцент l-фенилаланина (варианты), способ получения l-фенилаланина |
| US20050080268A1 (en) * | 2003-10-08 | 2005-04-14 | Yong-Moon Choi | Process of preparing O-carbamoyl compounds in the presence of active amine group |
| CA2587481A1 (en) | 2004-10-28 | 2006-05-11 | Sk Corporation | Phenylalkylamino carbamates adjunctive therapy for depression |
| ES2435403T3 (es) * | 2005-06-08 | 2013-12-19 | Sk Biopharmaceuticals Co., Ltd. | Tratamiento de trastornos del sueño y vigilia |
| ES2344469T3 (es) | 2005-06-22 | 2010-08-27 | Sk Holdings Co., Ltd. | Tratamiento de disfuncion sexual. |
| KR102173587B1 (ko) | 2009-06-22 | 2020-11-04 | 에스케이바이오팜 주식회사 | 피로의 치료 또는 예방 방법 |
| US8232315B2 (en) | 2009-06-26 | 2012-07-31 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating drug addiction and improving addiction-related behavior |
| MX350745B (es) | 2009-11-06 | 2017-09-14 | Sk Biopharmaceuticals Co Ltd * | El uso de un compuesto de carbamoilo para el tratamiento del sindrome de fibromialgia. |
| US8895609B2 (en) | 2009-11-06 | 2014-11-25 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating attention-deficit/hyperactivity disorder |
| US8623913B2 (en) | 2010-06-30 | 2014-01-07 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating restless legs syndrome |
| US9610274B2 (en) | 2010-06-30 | 2017-04-04 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating bipolar disorder |
| US9050302B2 (en) | 2013-03-01 | 2015-06-09 | Jazz Pharmaceuticals Ireland Limited | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters |
| US9359290B2 (en) | 2013-03-13 | 2016-06-07 | Jazz Pharmaceuticals International Iii Limited | Treatment of cataplexy |
| CN110638805A (zh) | 2013-07-12 | 2020-01-03 | 爵士制药国际Iii有限公司 | 促进吸烟停止 |
| KR102309836B1 (ko) | 2013-07-18 | 2021-10-12 | 에스케이바이오팜 주식회사 | 비만의 치료 |
| TWI698415B (zh) * | 2014-02-28 | 2020-07-11 | 南韓商愛思開生物製藥股份有限公司 | 胺基羰基胺基甲酸酯化合物 |
| CN109071454B (zh) | 2016-02-16 | 2023-02-17 | 昆士兰大学 | 磺酰脲和相关化合物及其用途 |
| ES2970887T3 (es) * | 2016-09-06 | 2024-05-31 | Axsome Malta Ltd | Forma de solvato de carbamato de (R)-2-amino-3-fenilpropilo |
| KR101950254B1 (ko) | 2016-09-21 | 2019-02-20 | 유상신 | 차량탑승자의 부재를 감지하는 지능형 카시트 |
| EP3837239A4 (en) * | 2018-08-14 | 2022-05-18 | Glenmark Life Sciences Limited | PROCESS FOR THE PREPARATION OF SOLRIAMFETOL AND SALT THEREOF |
-
2017
- 2017-09-06 ES ES17849432T patent/ES2970887T3/es active Active
- 2017-09-06 CN CN201780065192.6A patent/CN109996540A/zh active Pending
- 2017-09-06 CN CN202510706413.XA patent/CN120574152A/zh active Pending
- 2017-09-06 EP EP23218015.8A patent/EP4364794A3/en active Pending
- 2017-09-06 JP JP2019512895A patent/JP7219213B2/ja active Active
- 2017-09-06 FI FIEP17849432.4T patent/FI3509582T3/fi active
- 2017-09-06 WO PCT/US2017/050233 patent/WO2018048871A1/en not_active Ceased
- 2017-09-06 EP EP17849432.4A patent/EP3509582B1/en active Active
- 2017-09-06 US US16/331,069 patent/US10829443B2/en active Active
- 2017-09-06 CN CN202511369712.5A patent/CN121202731A/zh active Pending
- 2017-09-06 SG SG11201901998WA patent/SG11201901998WA/en unknown
- 2017-09-06 DK DK17849432.4T patent/DK3509582T3/da active
- 2017-09-06 CN CN202511369602.9A patent/CN121202730A/zh active Pending
- 2017-09-06 KR KR1020197011279A patent/KR102513800B1/ko active Active
- 2017-09-06 MY MYPI2019001180A patent/MY197630A/en unknown
- 2017-09-06 CA CA3036071A patent/CA3036071A1/en not_active Abandoned
-
2019
- 2019-03-06 PH PH12019500493A patent/PH12019500493A1/en unknown
-
2020
- 2020-11-06 US US17/091,222 patent/US11560354B2/en active Active
-
2021
- 2021-09-24 JP JP2021155292A patent/JP7642506B2/ja active Active
-
2022
- 2022-12-14 US US18/066,000 patent/US12384743B2/en active Active
-
2024
- 2024-09-19 JP JP2024161956A patent/JP2024178291A/ja active Pending
-
2025
- 2025-07-11 US US19/266,767 patent/US20250340509A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| SG11201901998WA (en) | 2019-04-29 |
| JP7219213B2 (ja) | 2023-02-07 |
| JP2024178291A (ja) | 2024-12-24 |
| KR20190065311A (ko) | 2019-06-11 |
| EP4364794A3 (en) | 2024-07-24 |
| EP4364794A2 (en) | 2024-05-08 |
| US10829443B2 (en) | 2020-11-10 |
| PH12019500493A1 (en) | 2019-05-27 |
| JP7642506B2 (ja) | 2025-03-10 |
| US20190194126A1 (en) | 2019-06-27 |
| US11560354B2 (en) | 2023-01-24 |
| JP2022003062A (ja) | 2022-01-11 |
| CN109996540A (zh) | 2019-07-09 |
| US20250340509A1 (en) | 2025-11-06 |
| US20230183172A1 (en) | 2023-06-15 |
| CA3036071A1 (en) | 2018-03-15 |
| ES2970887T3 (es) | 2024-05-31 |
| KR102513800B1 (ko) | 2023-03-24 |
| JP2019535643A (ja) | 2019-12-12 |
| EP3509582A1 (en) | 2019-07-17 |
| US12384743B2 (en) | 2025-08-12 |
| EP3509582A4 (en) | 2020-05-13 |
| CN120574152A (zh) | 2025-09-02 |
| US20210053912A1 (en) | 2021-02-25 |
| DK3509582T3 (en) | 2024-02-12 |
| MY197630A (en) | 2023-06-29 |
| EP3509582B1 (en) | 2023-12-20 |
| CN121202730A (zh) | 2025-12-26 |
| CN121202731A (zh) | 2025-12-26 |
| WO2018048871A1 (en) | 2018-03-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI3509582T3 (fi) | (r)-2-amino-3-fenyylipropyylikarbamaatin solvaattimuoto | |
| JP2019535643A5 (https=) | ||
| MX2024010140A (es) | Nuevos metodos. | |
| RU2020108634A (ru) | Аналоги карбамоилфенилаланинола и способы их применения | |
| JP2020530837A5 (https=) | ||
| RU2018102640A (ru) | Применение амитриптилина для блокирования мозговых гемиканалов и способ потенцирования его влияния in vivo | |
| JP2015110588A5 (https=) | ||
| MX383665B (es) | Composiciones de donepezilo y métodos para tratar la enfermedad de alzheimer. | |
| JP2019535760A5 (ja) | ガボキサドールを用いた注意欠陥多動性障害（ａｄｈｄ）の治療方法 | |
| JP2016512563A5 (https=) | ||
| IL292465B2 (en) | Neuroactive compounds and methods of use thereof | |
| JP2015517488A5 (https=) | ||
| JP2016518337A5 (https=) | ||
| MX2017013483A (es) | Compuestos y su uso como inhibidores de ?-secretasa 1 (bace1). | |
| JP2016503010A5 (https=) | ||
| JP2017537912A5 (https=) | ||
| BR112017013253A2 (pt) | comprimidos de desintegração oral, processo para produzir comprimido de desintegração oral contendo tofacitinibe ou seus sais farmaceuticamente aceitáveis, processo para produzir comprimido de desintegração oral, desintegrante, e edulcorantes | |
| WO2016015798A9 (en) | Orodispersible film composition comprising enalapril for the treatment of hypertension in a pediatric population | |
| RU2017105262A (ru) | Способы применения производных циклического амида для лечения опосредуемых сигма-рецепторами расстройств | |
| EP4431098A4 (en) | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OR PREVENTION OF ALPORT SYNDROME | |
| JP2014518280A5 (https=) | ||
| RU2016101248A (ru) | Лиофилизированные препараты бендамустина гидрохлорида | |
| RU2016127361A (ru) | Гастроретентивные фармацевтические композиции для перорального введения | |
| IL276576B2 (en) | Therapeutic agents for treating restless legs syndrome | |
| RU2013127794A (ru) | Фармацевтическая комбинация и композиция для лечения ожирения и ее применение |